3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Completed
5
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Motor Activity
34
Neoplasms
17
Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
5
Polycystic Ovary Syndrome
4
Lymphoma
4
Sarcopenia
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Fatigue
3
Colorectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pain
2
Ovarian Neoplasms
2
Obesity
2
Malnutrition
2
Lymphedema
2
Insulin Resistance
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Weight Cycling
1
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Interventions
venetoclax
22
Cyclophosphamide
14
Cytarabine
12
Azacitidine
8
fludarabine
7
Daunorubicin
5
ruxolitinib
4
revumenib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Dexamethasone
4
quizartinib
3
pirtobrutinib
3
gamma-Globulins
3
fludarabine phosphate
3
blinatumomab
3
Tacrolimus
3
Rituximab
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Decitabine
3
Ciprofloxacin
3
Blood Specimen Collection
3
zanubrutinib
2
pembrolizumab
2
ibrutinib
2
aldesleukin
2
acalabrutinib
2
Watchful Waiting
2
Mycophenolic Acid
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia
×
Exercise
×
Clear all
NCT06643221
2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
100 enrolled